My watch list
my.chemeurope.com  
Login  

Sanochemia acquires majority shareholding in AlcaSynn

21-Jun-2006

In the course of a venture capital transaction, Sanochemia Pharmazeutika AG has acquired a 60% holding in Innsbruck-based AlcaSynn Pharmaceuticals GmbH. Through its stake in this company, founded in 2002 by Prof. Dr. Helmut Schmidhammer and Dr. Johannes Schütz, Sanochemia has secured access to a broad technological base and extensive developmental resources in the fields of pain management and CNS.

In cooperation with leading pharmaceutical players, AlcaSynn develops drugs on the basis of synthetic morphinan derivatives with a marked pharmacological profile for the treatment of pain, inflammation, Parkinson's and Alzheimer's. The company is headed by Dr. Peter Kayatz (CEO) and Dr. Mariana Spetea (CSO) and currently holds a patent portfolio consisting of 13 awarded patents and a further 26 patents pending.

The leading product candidate, AS006, is a strong, peripherally-acting painkiller (100 times stronger than morphine) which does not exhibit the adverse side effects characteristic of other opiates including respiratory depression, drowsiness and potential addiction. AS006 is currently in pre-clinical testing with clinical trials scheduled to begin in 2008.

Sanochemia's shareholding in AlcaSynn Pharmaceuticals GmbH represents a major strategic addition to its potential as a provider of specialty pharmaceuticals in its existing development segments. Key for Sanochemia is the synergy potential offered by utilising its synthesis plant located in Neufeld, Austria.

Facts, background information, dossiers
  • Sanochemia
  • pain
  • AlcaSynn Pharmaceuticals
  • inflammation
  • depression
  • clinical trials
More about Sanochemia Pharmazeutika
  • News

    Sanochemia acquires majority shareholding in AlcaSynn

    In the course of a venture capital transaction, Sanochemia Pharmazeutika AG has acquired a 60% holding in Innsbruck-based AlcaSynn Pharmaceuticals GmbH. Through its stake in this company, founded in 2002 by Prof. Dr. Helmut Schmidhammer and Dr. Johannes Schütz, Sanochemia has secured access ... more

More about AlcaSynn Pharmaceuticals
  • News

    Sanochemia acquires majority shareholding in AlcaSynn

    In the course of a venture capital transaction, Sanochemia Pharmazeutika AG has acquired a 60% holding in Innsbruck-based AlcaSynn Pharmaceuticals GmbH. Through its stake in this company, founded in 2002 by Prof. Dr. Helmut Schmidhammer and Dr. Johannes Schütz, Sanochemia has secured access ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE